The competition watchdog will not oppose Mylan NV’s proposed merger with Pfizer’s Upjohn Inc after the global pharmaceutical giants agreed to sell several off-patent brands to dispel competition concerns.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?
Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.

For information on rights and reprints, contact subscriptions@lawyerly.com.au